Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of PT-Cy in Relapsed/Refractory AML Transplant
NCT02057770Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cyclophosphamide in acute myeloid leukemia (AML) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Event Free Survival rate at 100 days. Started Feb 2014; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02057770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057770.